Karl G Stonecipher,1,2 Gail L Torkildsen,3 George W Ousler III,4 Scot Morris,5 Linda Villanueva,6 David A Hollander6
1Department of Ophthalmology, University of North Carolina, Chapel Hill, 2TLC Laser Eye Centers, Greensboro, NC, 3Andover Eye Associates, 4Ora, Inc., Andover, MA, 5Eye Consultants of Colorado, Conifer, CO, 6Allergan plc, Irvine, CA, USA
Objective: The aim of this study was to evaluate the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye.
Methods: This was a single-center, 6-month, open-label, Phase IV study. Patients with bilateral dry eye disease and a symptom score of ≥2 on the Ocular Discomfort and 4-Symptom Questionnaire, an Ocular Surface Disease Index score of >12, at least one eye with Schirmer's score <10 mm/5 minutes, and central corneal staining graded as ≥2 on the Ora Calibra™ Corneal and Conjunctival Staining Scale were enrolled. Cyclosporine ophthalmic emulsion 0.05% (Restasis®) was instilled twice daily in each eye. The primary efficacy endpoints were ocular surface staining and visual function at 6 months. Secondary outcome measures included Schirmer's test, tear film breakup time, symptoms, and adverse events.
Results: A total of 40 patients with the mean age of 59.4 years (range, 40–78 years) were enrolled; 35 (87.5%) were female and 37 (92.5%) completed the study. At 6 months, inferior corneal, central corneal, total corneal, and total ocular surface fluorescein staining were significantly improved from baseline in both eyes (P<0.001). Patient responses on the Ocular Surface Disease Index showed significant improvement in blurred vision and visual function related to reading, driving at night, working with a computer or bank machine, and watching television (P≤0.041). At 6 months, 35.1% of patients achieved ≥5 mm improvement and 18.9% achieved ≥10 mm improvement in the average eye Schirmer score. Mean tear film breakup time improved by >50% in both eyes (P<0.001). Patients reported significant improvement in ocular discomfort and dry eye symptoms (P<0.001). No patients discontinued treatment because of stinging or any other ocular adverse event.
Conclusion: Dry eye patients with difficulties with day-to-day visual function demonstrated improvement in both signs and symptoms of dry eye and reported improved visual function after 6 months of treatment with cyclosporine ophthalmic emulsion 0.05%.
Keywords: corneal staining, dry eye disease, Ocular Surface Disease Index, ocular surface staining, visual function, clinical trial
from #Medicine via ola Kala on Inoreader http://ift.tt/1sqi6hB
via IFTTT
Αρχειοθήκη ιστολογίου
-
►
2023
(138)
- ► Φεβρουαρίου (74)
- ► Ιανουαρίου (64)
-
►
2022
(849)
- ► Δεκεμβρίου (61)
- ► Σεπτεμβρίου (74)
- ► Φεβρουαρίου (65)
-
►
2021
(2936)
- ► Δεκεμβρίου (59)
- ► Σεπτεμβρίου (180)
- ► Φεβρουαρίου (325)
-
►
2020
(1624)
- ► Δεκεμβρίου (293)
- ► Σεπτεμβρίου (234)
- ► Φεβρουαρίου (28)
-
►
2019
(13362)
- ► Δεκεμβρίου (19)
- ► Σεπτεμβρίου (54)
- ► Φεβρουαρίου (5586)
- ► Ιανουαρίου (5696)
-
►
2018
(66471)
- ► Δεκεμβρίου (5242)
- ► Σεπτεμβρίου (5478)
- ► Φεβρουαρίου (4835)
- ► Ιανουαρίου (5592)
-
►
2017
(44259)
- ► Δεκεμβρίου (5110)
- ► Σεπτεμβρίου (5105)
-
▼
2016
(7467)
- ► Δεκεμβρίου (514)
- ► Σεπτεμβρίου (1038)
-
▼
Μαΐου
(630)
-
▼
Μαΐ 22
(46)
- Clinical utility of the KAMRA corneal inlay
- Time of maximum cycloplegia after instillation of ...
- Ranibizumab in monotherapy and combined with photo...
- Segmentation and removal of fibrovascular membrane...
- Neurofibromatosis: an update of ophthalmic charact...
- Tear volume estimation using a modified Schirmer t...
- Ocular manifestations of Sturge–Weber syndrome: pa...
- The IMPACT study: a prospective evaluation of the ...
- An exploratory study evaluating the effects of mac...
- Pre- and postsynaptic effects of brimonidine on is...
- Comparison of intraocular pressure adjusted by cen...
- Comparison of visual outcomes and subjective visua...
- A randomized, double-blind, placebo-controlled stu...
- Effect of benzalkonium chloride-free latanoprost o...
- A nonrandomized, open-label study to evaluate the ...
- Risk factors for visual impairment associated with...
- Pharmacokinetics and aqueous humor penetration of ...
- Outcomes of excimer laser enhancements in pseudoph...
- Feasibility study of sustained-release travoprost ...
- Vitrectomy for center-involved diabetic macular edema
- Glycan Node Analysis: A Bottom-up Approach to Glyc...
- Light-driven Enzymatic Decarboxylation
- Assessment of Startle Response and Its Prepulse In...
- Plasma miR-10a: A Potential Biomarker for Coronary...
- Two-Year Follow-Up after Contact Force Sensing Rad...
- The Utility of a Digital Virtual Template for Juni...
- A Review of Animal Models of Intervertebral Disc D...
- Volatiles from Subtropical Convolvulaceae That Int...
- Unveiling alterative splice diversity from human o...
- Proteomic characterization of Nα- and Nε-acetylati...
- A proteomic signature of ovarian cancer tumor flui...
- Transcriptomic and proteomic analyses provide new ...
- A cost-effective method to get insight into the pe...
- Screening for target toxins of the antiophidic pro...
- Oncogenic KIT mutations in different exons lead to...
- From great kivas to great houses: Community format...
- Antigenic characterization of influenza viruses pr...
- A national examination of pharmacy-based immunizat...
- Report of the Cent Gardes HIV Vaccines Conference....
- The impact of implementing a demand forecasting sy...
- Humoral, T-cell and B-cell immune responses to sea...
- Effectiveness of seasonal trivalent influenza vacc...
- Ultrastructural Changes and Death of Leishmania in...
- Responding to the existentials of non-life-threate...
- Home-applied IPL epilation may prevent the problem...
- General vulnerability to stuttering: The experienc...
-
▼
Μαΐ 22
(46)
- ► Φεβρουαρίου (793)
Αναζήτηση αυτού του ιστολογίου
Κυριακή 22 Μαΐου 2016
The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Αλέξανδρος Γ. Σφακιανάκης Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,0030693260717...
-
heory of COVID-19 pathogenesis Publication date: November 2020Source: Medical Hypotheses, Volume 144Author(s): Yuichiro J. Suzuki ScienceD...
-
Alimentary Pharmacology &Therapeutics, EarlyView. https://ift.tt/2qECBIJ
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.